{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:56:34Z","timestamp":1779216994789,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"S6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010676","name":"H2020 Societal Challenges","doi-asserted-by":"publisher","award":["777123"],"award-info":[{"award-number":["777123"]}],"id":[{"id":"10.13039\/100010676","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tuberculosis (TB) represents a worldwide cause of mortality (it infects one third of the world\u2019s population) affecting mostly developing countries, including India, and recently also developed ones due to the increased mobility of the world population and the evolution of different new bacterial strains capable to provoke multi-drug resistance phenomena. Currently, antitubercular drugs are unable to eradicate subpopulations of <jats:italic>Mycobacterium tuberculosis<\/jats:italic> (MTB) bacilli and therapeutic vaccinations have been postulated to overcome some of the critical issues related to the increase of drug-resistant forms and the difficult clinical and public health management of tuberculosis patients. The Horizon 2020 EC funded project \u201cIn Silico Trial for Tuberculosis Vaccine Development\u201d (STriTuVaD) to support the identification of new therapeutic interventions against tuberculosis through novel in silico modelling of human immune responses to disease and vaccines, thereby drastically reduce the cost of clinical trials in this critical sector of public healthcare.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We present the application of the Universal Immune System Simulator (UISS) computational modeling infrastructure as a disease model for TB. The model is capable to simulate the main features and dynamics of the immune system activities i.e., the artificial immunity induced by RUTI\u00ae vaccine, a polyantigenic liposomal therapeutic vaccine made of fragments of <jats:italic>Mycobacterium tuberculosis<\/jats:italic> cells (FCMtb). Based on the available data coming from phase II Clinical Trial in subjects with latent tuberculosis infection treated with RUTI\u00ae and isoniazid, we generated simulation scenarios through validated data in order to tune UISS accordingly to STriTuVaD objectives. The first case simulates the establishment of MTB latent chronic infection with some typical granuloma formation; the second scenario deals with a reactivation phase during latent chronic infection; the third represents the latent chronic disease infection scenario during RUTI\u00ae vaccine administration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The application of this computational modeling strategy helpfully contributes to simulate those mechanisms involved in the early stages and in the progression of tuberculosis infection and to predict how specific therapeutical strategies will act in this scenario. In view of these results, UISS owns the capacity to open the door for a prompt integration of in silico methods within the pipeline of clinical trials, supporting and guiding the testing of treatments in patients affected by tuberculosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12859-019-3045-5","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T18:03:54Z","timestamp":1576001034000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Predicting the artificial immunity induced by RUTI\u00ae vaccine against tuberculosis using universal immune system simulator (UISS)"],"prefix":"10.1186","volume":"20","author":[{"given":"Marzio","family":"Pennisi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Sgroi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Bonaccorso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe Alessandro","family":"Parasiliti Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Epifanio","family":"Fichera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipendra Kumar","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth B.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere-Joan","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merce","family":"Amat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Viceconti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Pappalardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"key":"3045_CR1","doi-asserted-by":"crossref","unstructured":"Furin J, Cox H, Pai M. Tuberculosis. Lancet. 2019;393(10181):1642\u201356.","DOI":"10.1016\/S0140-6736(19)30308-3"},{"key":"3045_CR2","doi-asserted-by":"crossref","unstructured":"Koch A, Mizrahi V. Mycobacterium tuberculosis. Trends Microbiol. 2018;26(6):555\u201356.","DOI":"10.1016\/j.tim.2018.02.012"},{"key":"3045_CR3","volume-title":"WHO Global Tuberculosis Report 2018","author":"WHO","year":"2018","unstructured":"WHO. WHO Global Tuberculosis Report 2018. 2018."},{"key":"3045_CR4","unstructured":"Central TB Division. Annual Status report of Tb India 2016, Revised National TB Control Programme. J Chem Inf Model. 2013;53:1689\u201399."},{"key":"3045_CR5","doi-asserted-by":"crossref","unstructured":"Fogel N. Tuberculosis: a disease without boundaries. Tuberculosis. 2015;95(5):527\u201331.","DOI":"10.1016\/j.tube.2015.05.017"},{"key":"3045_CR6","doi-asserted-by":"crossref","unstructured":"Donald PR, Marais BJ, Barry CE. Age and the epidemiology and pathogenesis of tuberculosis. Lancet. 2010;375(9729):1852\u201354.","DOI":"10.1016\/S0140-6736(10)60580-6"},{"key":"3045_CR7","doi-asserted-by":"crossref","unstructured":"Cadena AM, Fortune SM, Flynn JL. Heterogeneity in tuberculosis. Nat Rev Immunol. 2017;17(11):691\u2013702.","DOI":"10.1038\/nri.2017.69"},{"key":"3045_CR8","doi-asserted-by":"publisher","unstructured":"Narasimhan P, Wood J, Macintyre CR, Mathai D. Risk factors for tuberculosis. Pulmonary Medicine. 2013;2013:828939. https:\/\/doi.org\/10.1155\/2013\/828939.","DOI":"10.1155\/2013\/828939"},{"key":"3045_CR9","doi-asserted-by":"crossref","unstructured":"Lo\u0308nnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med. 2009;68(12):2240\u201346.","DOI":"10.1016\/j.socscimed.2009.03.041"},{"key":"3045_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1440-1843.2010.01739.x","volume":"15","author":"K Dheda","year":"2010","unstructured":"Dheda K, Schwander SK, Zhu B, van RN Z-S, Zhang Y. The immunology of tuberculosis: from bench to bedside. Respirology. 2010;15:433\u201350. https:\/\/doi.org\/10.1111\/j.1440-1843.2010.01739.x.","journal-title":"Respirology."},{"key":"3045_CR11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1146\/annurev-immunol-032712-095939","volume":"31","author":"A O\u2019Garra","year":"2013","unstructured":"O\u2019Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MPR. The immune response in tuberculosis. Annu Rev Immunol. 2013;31:475\u2013527. https:\/\/doi.org\/10.1146\/annurev-immunol-032712-095939.","journal-title":"Annu Rev Immunol"},{"key":"3045_CR12","unstructured":"Cailleaux-Cezar M, De D, Xavier GM, CLG DS, FCQ DM, Ruffino-Netto A, et al. Tuberculosis incidence among contacts of active pulmonary tuberculosis. Int J Tuberc Lung Dis. 2009;13(2):190\u201395."},{"key":"3045_CR13","doi-asserted-by":"crossref","unstructured":"Lin PL, Flynn JL. Understanding Latent Tuberculosis: A Moving Target. J Immunol. 2010;185(1):15\u201322.","DOI":"10.4049\/jimmunol.0903856"},{"key":"3045_CR14","doi-asserted-by":"crossref","unstructured":"Tufariello JAM, Chan J, Flynn JAL. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis. 2003;3(9):578\u201390.","DOI":"10.1016\/S1473-3099(03)00741-2"},{"key":"3045_CR15","doi-asserted-by":"crossref","unstructured":"Rockwood N, du Bruyn E, Morris T, Wilkinson RJ. Assessment of treatment response in tuberculosis: Expert Review of Respiratory Medicine; 2016;10(6):643\u201354.","DOI":"10.1586\/17476348.2016.1166960"},{"key":"3045_CR16","doi-asserted-by":"crossref","unstructured":"Sotgiu G, Centis R, D\u2019Ambrosio L, Battista Migliori G. Tuberculosis treatment and drug regimens. Cold Spring Harb Perspect Med. 2015;5(5):a017822.","DOI":"10.1101\/cshperspect.a017822"},{"key":"3045_CR17","doi-asserted-by":"crossref","unstructured":"Diel R, Hitte Nl, Schaberg T. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba\u2122 to background regimens in Germany. Respiratory Medicine. 2015;109(5):632\u201341.","DOI":"10.1016\/j.rmed.2015.01.017"},{"key":"3045_CR18","doi-asserted-by":"crossref","unstructured":"Kerantzas CA, Jacobs WR. Origins of combination therapy for tuberculosis: Lessons for future antimicrobial development and application. mBio. 2017;8(2):e01586\u201316.","DOI":"10.1128\/mBio.01586-16"},{"key":"3045_CR19","doi-asserted-by":"crossref","unstructured":"Tiberi S, Scardigli A, Centis R, D\u2019Ambrosio L, Mun\u0303oz-Torrico M, Salazar- Lezama MA\u0301, et al. Classifying new anti-tuberculosis drugs: rationale and future perspectives. Int J Infect Dis. 2017;56:181\u201384.","DOI":"10.1016\/j.ijid.2016.10.026"},{"key":"3045_CR20","doi-asserted-by":"crossref","unstructured":"Tiberi S, Mu\u00f1oz-Torrico M, Duarte R, Dalcolmo M, D\u2019Ambrosio L, Migliori GB. New drugs and perspectives for new anti-tuberculosis regimens. Rev Port Pneumol (English Edition). 2018.","DOI":"10.1016\/j.rppnen.2017.10.009"},{"key":"3045_CR21","volume-title":"Tuberculosis - Current Issues in Diagnosis and Management","author":"H Nath","year":"2013","unstructured":"Nath H, Ryoo S. First\u2013 and second\u2013line drugs and drug resistance. In: Tuberculosis - Current Issues in Diagnosis and Management; 2013."},{"key":"3045_CR22","doi-asserted-by":"crossref","unstructured":"Zumla A, Chakaya J, Centis R, D\u2019Ambrosio L, Mwaba P, Bates M, et al. Tuberculosis treatment and management-an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir Med. 2015;3(3):220\u201334.","DOI":"10.1016\/S2213-2600(15)00063-6"},{"key":"3045_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1055\/s-0038-1660863","volume":"39","author":"MK Haas","year":"2018","unstructured":"Haas MK, Belknap RW. Updates in the treatment of active and latent tuberculosis. Semin Respir Crit Care Med. 2018;39:297\u2013309.","journal-title":"Semin Respir Crit Care Med"},{"key":"3045_CR24","doi-asserted-by":"crossref","unstructured":"Getahun H, Matteelli A, Abubakar I, Abdel Aziz M, Baddeley A, Barreira D, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46(6):1563\u201376.","DOI":"10.1183\/13993003.01245-2015"},{"key":"3045_CR25","unstructured":"Silva Miranda M, Breiman A, Allain S, Deknuydt F, Altare F. The tuberculous 607granuloma: An unsuccessful host defence mechanism providing a safety 608shelter for the bacteria? Clin Dev Immunol. 2012;2012(2012):139127."},{"key":"3045_CR26","unstructured":"Oxlade O, Schwartzman K, Behr MA, Benedetti A, Pai M, Heymann J, et al. Global tuberculosis trends: a reflection of changes in tuberculosis control or in population health? Int J Tuberc Lung Dis. 2009;13(10):1238\u201346."},{"key":"3045_CR27","doi-asserted-by":"crossref","unstructured":"Schrager LK, Harris RC, Vekemans J. Research and development of new tuberculosis vaccines: a review. F1000Research. 2019;7:1732.","DOI":"10.12688\/f1000research.16521.2"},{"key":"3045_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.00894","volume":"10","author":"SA Prabowo","year":"2019","unstructured":"Prabowo SA, Painter H, Zelmer A, Smith SG, Seifert K, Amat M, et al. RUTI Vaccination Enhances Inhibition of Mycobacterial Growth ex vivo and Induces a Shift of Monocyte Phenotype in Mice. Front Immunol. 2019;10:1\u201310.","journal-title":"Front Immunol"},{"key":"3045_CR29","doi-asserted-by":"publisher","first-page":"e89612","DOI":"10.1371\/journal.pone.0089612","volume":"9","author":"AS Nell","year":"2014","unstructured":"Nell AS, D\u2019lom E, Bouic P, Sabat\u00e9 M, Bosser R, Picas J, et al. Safety, tolerability, and immunogenicity of the novel Antituberculous vaccine RUTI: randomized. Placebo-Controlled Phase II Clinical Trial in Patients with Latent Tuberculosis Infection PLoS One. 2014;9:e89612. https:\/\/doi.org\/10.1371\/journal.pone.0089612.","journal-title":"Placebo-Controlled Phase II Clinical Trial in Patients with Latent Tuberculosis Infection PLoS One"},{"key":"3045_CR30","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.vaccine.2009.09.134","volume":"28","author":"C Vilaplana","year":"2010","unstructured":"Vilaplana C, Montan\u00e9 E, Pinto S, Barriocanal AM, Domenech G, Torres F, et al. Double-blind, randomized, placebo-controlled phase I clinical trial of the therapeutical antituberculous vaccine RUTI\u00ae. Vaccine. 2010;28:1106\u201316. https:\/\/doi.org\/10.1016\/j.vaccine.2009.09.134.","journal-title":"Vaccine"},{"key":"3045_CR31","doi-asserted-by":"crossref","unstructured":"Javaid A, Ahmad N, Afridi AK, Basit A, Khan AH, Ahmad I, et al. Validity of time to sputum culture conversion to predict cure in patients with multidrug-resistant tuberculosis: a retrospective single-center study. Am J Trop Med Hyg. 2018;98(6):1629\u201336.","DOI":"10.4269\/ajtmh.17-0936"},{"key":"3045_CR32","doi-asserted-by":"publisher","unstructured":"Pappalardo F, Russo G, Tshinanu FM, Viceconti M. In silico clinical trials: concepts and early adoptions. Brief Bioinform. 2018:1\u201310. https:\/\/doi.org\/10.1093\/bib\/bby043.","DOI":"10.1093\/bib\/bby043"},{"key":"3045_CR33","doi-asserted-by":"crossref","unstructured":"Carlier A, Vasilevich A, Marechal M, De Boer J, Geris L. In silico clinical trials for pediatric orphan diseases. Sci Rep. 2018;6;8(1):2465.","DOI":"10.1038\/s41598-018-20737-y"},{"key":"3045_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.18203\/2349-3259.ijct20161408","volume":"3","author":"M Viceconti","year":"2016","unstructured":"Viceconti M, Henney A, Morley-Fletcher E. In silico clinical trials: how computer simulation will transform the biomedical industry. Int J Clin Trials. 2016;3:37. https:\/\/doi.org\/10.18203\/2349-3259.ijct20161408.","journal-title":"Int J Clin Trials"},{"key":"3045_CR35","volume-title":"Proceedings - 2018 IEEE international conference on bioinformatics and biomedicine, BIBM 2018","author":"F Pappalardo","year":"2019","unstructured":"Pappalardo F, Russo G, Pennisi M, Sgroi G, Alessandro G, Palumbo P, et al. Agent based modeling of relapsing multiple sclerosis: A possible approach to predict treatment outcome. In: Proceedings - 2018 IEEE international conference on bioinformatics and biomedicine, BIBM 2018; 2019."},{"key":"3045_CR36","doi-asserted-by":"publisher","first-page":"e26523","DOI":"10.1371\/journal.pone.0026523","volume":"6","author":"F Pappalardo","year":"2011","unstructured":"Pappalardo F, Forero IM, Pennisi M, Palazon A, Melero I, Motta S. SimB16: modeling induced immune system response against B16-melanoma. PLoS One. 2011;6:e26523. https:\/\/doi.org\/10.1371\/journal.pone.0026523.","journal-title":"PLoS One"},{"key":"3045_CR37","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1186\/s12859-017-1961-9","volume":"18","author":"M Pennisi","year":"2017","unstructured":"Pennisi M, Russo G, Ravalli S, Pappalardo F. Combining agent based-models and virtual screening techniques to predict the best citrus-derived vaccine adjuvants against human papilloma virus. BMC Bioinformatics. 2017;18:544. https:\/\/doi.org\/10.1186\/s12859-017-1961-9.","journal-title":"BMC Bioinformatics"},{"key":"3045_CR38","doi-asserted-by":"publisher","first-page":"7755","DOI":"10.1158\/0008-5472.CAN-10-0701","volume":"70","author":"A Palladini","year":"2010","unstructured":"Palladini A, Nicoletti G, Pappalardo F, Murgo A, Grosso V, Stivani V, et al. In silico modeling and in vivo efficacy of cancer-preventive vaccinations. Cancer Res. 2010;70:7755\u201363. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-0701.","journal-title":"Cancer Res"},{"key":"3045_CR39","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1093\/bioinformatics\/btv172","volume":"31","author":"F Gullo","year":"2015","unstructured":"Gullo F, van der Garde M, Russo G, Pennisi M, Motta S, Pappalardo F, et al. Computational modeling of the expansion of human cord blood CD133 + hematopoietic stem\/progenitor cells with different cytokine combinations. Bioinformatics. 2015;31:2514\u201322. https:\/\/doi.org\/10.1093\/bioinformatics\/btv172.","journal-title":"Bioinformatics"},{"key":"3045_CR40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jim.2015.08.014","volume":"427","author":"M Pennisi","year":"2015","unstructured":"Pennisi M, Russo G, Motta S, Pappalardo F. Agent based modeling of the effects of potential treatments over the blood\u2013brain barrier in multiple sclerosis. J Immunol Methods. 2015;427:6\u201312. https:\/\/doi.org\/10.1016\/j.jim.2015.08.014.","journal-title":"J Immunol Methods"},{"issue":"Suppl 16","key":"3045_CR41","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1186\/1471-2105-14-S16-S9","volume":"14","author":"M Pennisi","year":"2013","unstructured":"Pennisi M, Rajput A-M, Toldo L, Pappalardo F. Agent based modeling of Treg-Teff cross regulation in relapsing-remitting multiple sclerosis. BMC Bioinformatics. 2013;14(Suppl 16):S9. https:\/\/doi.org\/10.1186\/1471-2105-14-S16-S9.","journal-title":"BMC Bioinformatics"},{"key":"3045_CR42","doi-asserted-by":"crossref","unstructured":"Pappalardo F, Motta S, Lollini PL, Mastriani E. Analysis of vaccine\u2019s schedules using models. Cell Immunol. 2006;244(2):137\u201340.","DOI":"10.1016\/j.cellimm.2007.03.002"},{"key":"3045_CR43","volume-title":"Proceedings - 2018 IEEE international conference on bioinformatics and biomedicine, BIBM 2018","author":"F Pappalardo","year":"2019","unstructured":"Pappalardo F, Russo G, Pennisi M, Sgroi G, Alessandro G, Palumbo P, et al. An agent based modeling approach for the analysis of tuberculosis - Immune system dynamics. In: Proceedings - 2018 IEEE international conference on bioinformatics and biomedicine, BIBM 2018; 2019."},{"key":"3045_CR44","doi-asserted-by":"crossref","unstructured":"Castiglione F, Duca K, Jarrah A, Laubenbacher R, Hochberg D, Thorley-Lawson D. Simulating Epstein-Barr virus infection with C-ImmSim. Bioinformatics. 2007;23(11):1371\u201377","DOI":"10.1093\/bioinformatics\/btm044"},{"key":"3045_CR45","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3892\/ol.2015.4031","volume":"11","author":"S Hafsi","year":"2016","unstructured":"Hafsi S, Candido S, Maestro R, L F, Soua Z, Bonavida B, et al. correlation between the overexpression of yin Yang 1 and the expression levels of miRNAs in Burkitt\u2019s lymphoma: a computational study. Oncol Lett. 2016;11:1021\u20135. https:\/\/doi.org\/10.3892\/ol.2015.4031.","journal-title":"Oncol Lett"},{"key":"3045_CR46","doi-asserted-by":"publisher","unstructured":"Polo A, Crispo A, Cerino P, Falzone L, Candido S, Giudice A, et al. Environment and bladder cancer: molecular analysis by interaction networks. Oncotarget. 2017;8:65240\u201352. https:\/\/doi.org\/10.18632\/oncotarget.18222.","DOI":"10.18632\/oncotarget.18222"},{"key":"3045_CR47","doi-asserted-by":"crossref","unstructured":"An G, Fitzpatrick BG, Christley S, Federico P, Kanarek A, Neilan RM, et al. Optimization and control of agent-based models in biology: a perspective. Bull Math Biol. 2017;79(1):63\u201387.","DOI":"10.1007\/s11538-016-0225-6"},{"key":"3045_CR48","doi-asserted-by":"crossref","unstructured":"Shay JW, Wright WE. Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol. 2000;1(1):72\u201376.","DOI":"10.1038\/35036093"},{"key":"3045_CR49","volume-title":"Mobile DNA III","author":"Related Mechanisms of Antibody Somatic Hypermutation and Class Switch Recombination","year":"2015","unstructured":"Related Mechanisms of Antibody Somatic Hypermutation and Class Switch Recombination. In: Mobile DNA III. 2015."},{"key":"3045_CR50","volume-title":"Health Physics","author":"EJ Hall","year":"2003","unstructured":"Hall EJ. The bystander effect. In: Health Physics. 2003."}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-019-3045-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12859-019-3045-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-019-3045-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:29:37Z","timestamp":1607473777000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-019-3045-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":50,"journal-issue":{"issue":"S6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3045"],"URL":"https:\/\/doi.org\/10.1186\/s12859-019-3045-5","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"12 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"504"}}